dicumarol and Ischemic-Attack--Transient

Topics: Clinical Trials as Topic; Dicumarol; Drug Evaluation; Humans; Ischemic Attack, Transient; Protein Binding; Warfarin

62 patients with transient ischemic attack (TIA), 60 with reversible ischemic neurologic deficit (RIND) and 57 with stroke with minimum residuum (SMR) were followed, in a retrospective survey, from the first 7 days to the 3rd month of evolution. 90 received anticoagulant treatment, 66 antiplatelet treatment and 23 other or no treatment. 5 patients developed strokes with moderate or severe disability; no patient suffered a myocardial infarction or died. No influence of the type of treatment or of the clinical group (TIA, RIND and SMR) on the follow-up complications could be detected. There seems to be a group with a greater risk of developing further cerebral infarction, which is characterized by the occurrence of multiple TIAs for several days before the event.

Topics: Anticoagulants; Aspirin; Brain Ischemia; Dicumarol; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin; Humans; Ischemic Attack, Transient; Male; Middle Aged

Topics: Aspirin; Brain Ischemia; Carotid Arteries; Dicumarol; Dipyridamole; Endarterectomy; Heart Murmurs; Heparin; Humans; Hypertension; Ischemic Attack, Transient; Risk; Sulfinpyrazone; Warfarin

Topics: Adult; Alcoholism; Brain Diseases; Dicumarol; Humans; Ischemic Attack, Transient; Middle Aged

Topics: Aged; Cerebral Arterial Diseases; Dementia; Dicumarol; Humans; Ischemic Attack, Transient; Prothrombin Time

Topics: Blood Pressure Determination; Cerebral Hemorrhage; Dicumarol; Health Surveys; Heparin; Humans; Hypertension; Infarction; Intracranial Embolism and Thrombosis; Ischemic Attack, Transient; Prothrombin Time